What it sells
AI drug discovery platform for neurotherapeutics
Business model breakdown
Workflow: what inputs become what output?
Multimodal AI target discovery platform predicts a drug candidate's potential across multiple neural disorders simultaneously, modality-agnostic, targeting neural circuits.
Economics: what it saves and how it charges
UnverifiedPreclinical drug-discovery company; value comes from discovered neurotherapeutic candidates (licensing/partnering, hypothesis); no product revenue stated.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2025 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.